Latest Stories from Medical

Kaiser Permanente with Eight-Time NBA All-Star Chris Paul Hosts Basketball Clinic for Special Olympics Athletes

2015-03-21T15:00:08-07:00

NBA All-Star Chris Paul joins Kaiser Permanente in welcoming two Special Olympics basketball teams to a private basketball clinic at the Crenshaw Family YMCA in Los Angeles.

Samsung Health and Medical Equipment Sponsors Heart Across America Cycling Tour Kicking Off March 22

2015-03-21T07:00:02-07:00

Samsung to demonstrate ultrasound technology in stroke detection on nationwide cycling tour, led by former Intel executive Sean Maloney, to generate awareness about preventing stroke

Data Presented at the 30th European Association of Urology (EAU) Congress Further Assesses Efficacy, Safety and Tolerability of ZYTIGA® (Abiraterone Acetate) in Both Pre- and Post- Chemotherapy Settings in mCRPC

2015-03-21T02:46:08-07:00

La Terra Fina Recalls Organic Spinach Dip Sold in Bay Area Costco Clubs

2015-03-20T19:01:10-07:00

TransEnterix Issues Statement Required by NYSE MKT Rule 610(b)

2015-03-20T14:30:01-07:00

Cerulean Appoints Chris Guiffre President & Chief Executive Officer

2015-03-20T13:41:08-07:00

Paul Friedman to continue to serve as Executive Chairman and Bill Rastetter to continue to serve as Lead Independent Director

Macrophage Therapeutics to Expand Efforts Into CNS Diseases

2015-03-20T12:11:08-07:00

- Initiative based on data that targeted delivery technology crosses blood brain barrier -

HealthTrust Announces Innovation Summit and Invites Supplier Participation

2015-03-20T12:06:09-07:00

HealthTrust invites suppliers to submit new healthcare-related technology products for possible inclusion in its first Innovation Summit. Deadline is March 31.

Noven Files Patent Infringement Lawsuit Against Actavis

2015-03-20T11:43:09-07:00

QSpex Launches Its Same-Day Personalized Prescription Eyewear Delivery Model in New York City

2015-03-20T11:00:11-07:00

Company Opens Optical Service Center to Service the Eye-care Providers in New York City

Pershing Square Corrects Inaccurate Press Reports

2015-03-20T10:47:02-07:00

Emergency Departments Unite to Combat Epidemic of Opioid Over-Prescribing and Avoidable Death

2015-03-20T10:45:08-07:00

Prescription Drug Abuse Medical Task Force Announces Los Angeles County-wide Plan

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

2015-03-20T10:01:15-07:00

Nearly double the percentage of patients on BI 655066 with clear or almost clear skin (PASI 90) after 12 weeks vs. ustekinumab1 BI 655066 selectively blocks IL-23, a key protein involved in psoriatic skin inflammation1

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

2015-03-20T10:01:08-07:00

Nearly double the percentage of patients on BI 655066* with clear or almost clear skin (PASI 90) after 12 weeks vs. ustekinumab BI 655066 selectively blocks IL-23, a key protein involved in psoriatic skin inflammation

Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

2015-03-20T10:00:24-07:00

Improvements in the severity of preexisting nail, scalp and palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA responders through week 52 in ESTEEM 2 OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials Long-term safety profile for up to 104 weeks in ESTEEM 1 was consistent with previously reported data from OTEZLA clinical trial programs, with no new safety signals and no clinically meaningful changes in laboratory values